A new publication involving bradykinin signaling was released on August 17, 2026. The study, titled "BDKRB2 upregulation by dystrophic microglia drives pain hypersensitivity in aged mice," appeared in Acta Pharmacologica Sinica.
Bradykinin remains classified as an unapproved research compound. The publication is indexed under PubMed ID 42608526 and is available through the linked source.
This brief reports only that the publication exists, along with its title, journal, and date, as provided in the event record. No findings, results, or conclusions from the study are summarized here. Readers interested in the details of the research should consult the original publication directly.
For general background on bradykinin, readers can consult the compound overview.